A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06772766
- Locations
- 🇨🇳
The first Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳Hainan General Hospital, Haikou, Hainan, China
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT06752746
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06389942
- Locations
- 🇨🇳
PKUcare Luzhong Hospital, Zibo, Shandong, China
A Study of DISC-3405 in Healthy Volunteers
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Disc Medicine, Inc
- Target Recruit Count
- 64
- Registration Number
- NCT06050915
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath